Your browser doesn't support javascript.
loading
Genotype-first approach to identify associations between CDH1 germline variants and cancer phenotypes: a multicentre study by the European Reference Network on Genetic Tumour Risk Syndromes.
Garcia-Pelaez, José; Barbosa-Matos, Rita; Lobo, Silvana; Dias, Alexandre; Garrido, Luzia; Castedo, Sérgio; Sousa, Sónia; Pinheiro, Hugo; Sousa, Liliana; Monteiro, Rita; Maqueda, Joaquin J; Fernandes, Susana; Carneiro, Fátima; Pinto, Nádia; Lemos, Carolina; Pinto, Carla; Teixeira, Manuel R; Aretz, Stefan; Bajalica-Lagercrantz, Svetlana; Balmaña, Judith; Blatnik, Ana; Benusiglio, Patrick R; Blanluet, Maud; Bours, Vincent; Brems, Hilde; Brunet, Joan; Calistri, Daniele; Capellá, Gabriel; Carrera, Sergio; Colas, Chrystelle; Dahan, Karin; de Putter, Robin; Desseignés, Camille; Domínguez-Garrido, Elena; Egas, Conceição; Evans, D Gareth; Feret, Damien; Fewings, Eleanor; Fitzgerald, Rebecca C; Coulet, Florence; Garcia-Barcina, María; Genuardi, Maurizio; Golmard, Lisa; Hackmann, Karl; Hanson, Helen; Holinski-Feder, Elke; Hüneburg, Robert; Krajc, Mateja; Lagerstedt-Robinson, Kristina; Lázaro, Conxi.
Afiliação
  • Garcia-Pelaez J; Instituto de Investigação e Inovação em Saúde (i3S), University of Porto, Porto, Portugal; Faculty of Medicine, University of Porto, Porto, Portugal; Instituto de Patologia e Imunologia Molecular da Universidade do Porto, Porto, Portugal; Porto Comprehensive Cancer Center Raquel Seruca, Porto, Portu
  • Barbosa-Matos R; Instituto de Investigação e Inovação em Saúde (i3S), University of Porto, Porto, Portugal; Institute of Biomedical Sciences Abel Salazar, University of Porto, Porto, Portugal; Instituto de Patologia e Imunologia Molecular da Universidade do Porto, Porto, Portugal; Porto Comprehensive Cancer Center R
  • Lobo S; Instituto de Investigação e Inovação em Saúde (i3S), University of Porto, Porto, Portugal; Institute of Biomedical Sciences Abel Salazar, University of Porto, Porto, Portugal; Instituto de Patologia e Imunologia Molecular da Universidade do Porto, Porto, Portugal; Porto Comprehensive Cancer Center R
  • Dias A; Instituto de Investigação e Inovação em Saúde (i3S), University of Porto, Porto, Portugal; Instituto de Patologia e Imunologia Molecular da Universidade do Porto, Porto, Portugal; Porto Comprehensive Cancer Center Raquel Seruca, Porto, Portugal.
  • Garrido L; Centro Hospitalar Universitário São João, Porto, Portugal.
  • Castedo S; Instituto de Investigação e Inovação em Saúde (i3S), University of Porto, Porto, Portugal; Faculty of Medicine, University of Porto, Porto, Portugal; Instituto de Patologia e Imunologia Molecular da Universidade do Porto, Porto, Portugal; Centro Hospitalar Universitário São João, Porto, Portugal; Po
  • Sousa S; Instituto de Investigação e Inovação em Saúde (i3S), University of Porto, Porto, Portugal; Instituto de Patologia e Imunologia Molecular da Universidade do Porto, Porto, Portugal; Porto Comprehensive Cancer Center Raquel Seruca, Porto, Portugal.
  • Pinheiro H; Instituto de Investigação e Inovação em Saúde (i3S), University of Porto, Porto, Portugal; Instituto de Patologia e Imunologia Molecular da Universidade do Porto, Porto, Portugal; Serviço de Medicina Interna, Centro Hospitalar Tâmega e Sousa, Penafiel, Portugal; Porto Comprehensive Cancer Center Raq
  • Sousa L; Instituto de Investigação e Inovação em Saúde (i3S), University of Porto, Porto, Portugal; Instituto de Patologia e Imunologia Molecular da Universidade do Porto, Porto, Portugal; Escola de Economia e Gestão, Universidade do Minho, Braga, Portugal; Porto Comprehensive Cancer Center Raquel Seruca, Po
  • Monteiro R; Instituto de Investigação e Inovação em Saúde (i3S), University of Porto, Porto, Portugal; Instituto de Patologia e Imunologia Molecular da Universidade do Porto, Porto, Portugal.
  • Maqueda JJ; Instituto de Investigação e Inovação em Saúde (i3S), University of Porto, Porto, Portugal; Instituto de Patologia e Imunologia Molecular da Universidade do Porto, Porto, Portugal; Bioinf2Bio, Porto, Portugal.
  • Fernandes S; Instituto de Investigação e Inovação em Saúde (i3S), University of Porto, Porto, Portugal.
  • Carneiro F; Instituto de Investigação e Inovação em Saúde (i3S), University of Porto, Porto, Portugal; Faculty of Medicine, University of Porto, Porto, Portugal; Instituto de Patologia e Imunologia Molecular da Universidade do Porto, Porto, Portugal; Centro Hospitalar Universitário São João, Porto, Portugal; Po
  • Pinto N; Instituto de Investigação e Inovação em Saúde (i3S), University of Porto, Porto, Portugal; Center of Mathematics, University of Porto, Porto, Portugal; Instituto de Patologia e Imunologia Molecular da Universidade do Porto, Porto, Portugal; Porto Comprehensive Cancer Center Raquel Seruca, Porto, Por
  • Lemos C; Instituto de Investigação e Inovação em Saúde (i3S), University of Porto, Porto, Portugal; Institute of Biomedical Sciences Abel Salazar, University of Porto, Porto, Portugal; Institute for Molecular and Cell Biology, University of Porto, Porto, Portugal; Porto Comprehensive Cancer Center Raquel Ser
  • Pinto C; Department of Laboratory Genetics, Portuguese Oncology Institute of Porto, Porto, Portugal; Porto Comprehensive Cancer Center Raquel Seruca, Porto, Portugal.
  • Teixeira MR; Institute of Biomedical Sciences Abel Salazar, University of Porto, Porto, Portugal; Department of Laboratory Genetics, Portuguese Oncology Institute of Porto, Porto, Portugal; Porto Comprehensive Cancer Center Raquel Seruca, Porto, Portugal; European Reference Network on Genetic Tumour Risk Syndrom
  • Aretz S; Institute of Human Genetics, Medical Faculty, University of Bonn, Bonn, Germany; National Center for Hereditary Tumor Syndromes, University Hospital Bonn, Bonn, Germany; ERN GENTURIS, Bonn, Germany.
  • Bajalica-Lagercrantz S; Department of Oncology-Pathology, Karolinska Institutet, Stockholm, Sweden; Department of Clinical Genetics, Cancer Genetic Unit, Karolinska University Hospital Solna, Stockholm, Sweden; Cancer Theme, Karolinska University Hospital Solna, Stockholm, Sweden; ERN GENTURIS, Stockholm, Sweden.
  • Balmaña J; Hospital Vall d'Hebron, Universitat Autonoma de Barcelona, Barcelona, Spain; ERN GENTURIS, Barcelona, Spain.
  • Blatnik A; Department of Clinical Cancer Genetics, Institute of Oncology Ljubljana, Ljubljana, Slovenia; ERN GENTURIS, Ljubljana, Slovenia.
  • Benusiglio PR; Medical Genetics Department, Pitié-Salpêtrière Hospital, AP-HP and Sorbonne University, Paris, France.
  • Blanluet M; Service de Génétique Oncologique, Institut Curie, Paris, France.
  • Bours V; Laboratory of Human Genetics, GIGA Institute, University of Liège, Liège, Belgium; Center of Genetics, University Hospital, Liège, Belgium; ERN GENTURIS, Liège, Belgium.
  • Brems H; Department of Human Genetics, University of Leuven, Leuven, Belgium.
  • Brunet J; Hereditary Cancer Programme, Catalan Institute of Oncology, Bellvitge Institute for Biomedical Research and Girona Biomedical Research Institute, Barcelona-Girona, Spain; ERN GENTURIS, Barcelona, Spain.
  • Calistri D; Laboratorio di Bioscienze, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) "Dino Amadori", Meldola, Italy.
  • Capellá G; Hereditary Cancer Program, Catalan Institute of Oncology, Bellvitge Institute for Biomedical Research, Barcelona, Spain; Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Madrid, Spain; ERN GENTURIS, Barcelona, Spain.
  • Carrera S; Oncology Service, Biocruces Bizkaia Health Research Institute, Cruces University Hospital, Cruces-Barakaldo, Bizkaia, Spain.
  • Colas C; Service de Génétique Oncologique, Institut Curie, Paris, France; ERN GENTURIS, Paris, France.
  • Dahan K; Center of Human Genetics, IPG, Gosselies, Belgium.
  • de Putter R; Clinical Genetics Department, University Hospital of Ghent, Ghent, Belgium; ERN GENTURIS, Ghent, Belgium.
  • Desseignés C; Medical Genetics Department, Pitié-Salpêtrière Hospital, AP-HP and Sorbonne University, Paris, France.
  • Domínguez-Garrido E; Molecular Diagnostics Laboratory, Fundación Rioja Salud, Logroño, Spain.
  • Egas C; CNC-Center for Neuroscience and Cell Biology, University of Coimbra, Coimbra, Portugal.
  • Evans DG; Division of Evolution and Genomic Sciences, University of Manchester, Manchester, UK; Manchester Centre for Genomic Medicine, Manchester, UK.
  • Feret D; Center of Human Genetics, IPG, Gosselies, Belgium.
  • Fewings E; Department of Medical Genetics, National Institute for Health Research Cambridge Biomedical Research Centre, University of Cambridge, Cambridge, UK.
  • Fitzgerald RC; Early Cancer Institute, University of Cambridge, Cambridge, UK.
  • Coulet F; Medical Genetics Department, Pitié-Salpêtrière Hospital, AP-HP and Sorbonne University, Paris, France.
  • Garcia-Barcina M; Genetics Unit, Biocruces Bizkaia Health Research Institute, Basurto University Hospital, Bilbao, Bizkaia, Spain.
  • Genuardi M; Sezione di Medicina Genomica, Dipartimento di Scienze della Vita e Salute Pubblica, Università Cattolica del Sacro Cuore, Rome, Italy; UOC Genetica Medica, Dipartimento di Scienze di Laboratorio e Infettivologiche, Fondazione Policlinico Universitario A Gemelli IRCCS, Rome, Italy; ERN GENTURIS, Rome
  • Golmard L; Service de Génétique Oncologique, Institut Curie, Paris, France.
  • Hackmann K; Institute for Clinical Genetics, University Hospital Carl Gustav Carus and Faculty of Medicine, Technische Universität Dresden, Dresden, Germany; National Center for Tumor Diseases, Dresden, Germany: German Cancer Research Center, Heidelberg, Germany; Helmholtz-Zentrum Dresden-Rossendorf, Dresden, G
  • Hanson H; SouthWest Thames Regional Genetics Service, St George's University Hospitals NHS Foundation Trust, London, UK.
  • Holinski-Feder E; Medizinische Klinik und Poliklinik IV, Klinikum der Universität München, Munich, Germany; Medizinisch Genetisches Zentrum, Munich, Germany; ERN GENTURIS, Munich, Germany.
  • Hüneburg R; Department of Internal Medicine I, University Hospital Bonn, Bonn, Germany; National Center for Hereditary Tumor Syndromes, University Hospital Bonn, Bonn, Germany; ERN GENTURIS, Bonn, Germany.
  • Krajc M; Department of Clinical Cancer Genetics, Institute of Oncology Ljubljana, Ljubljana, Slovenia; ERN GENTURIS, Ljubljana, Slovenia.
  • Lagerstedt-Robinson K; Department of Oncology-Pathology, Karolinska Institutet, Stockholm, Sweden; Department of Clinical Genetics, Cancer Genetic Unit, Karolinska University Hospital Solna, Stockholm, Sweden; ERN GENTURIS, Stockholm, Sweden.
  • Lázaro C; Hereditary Cancer Program, Catalan Institute of Oncology, Bellvitge Institute for Biomedical Research, Barcelona, Spain; Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Madrid, Spain; ERN GENTURIS, Barcelona, Spain.
Lancet Oncol ; 24(1): 91-106, 2023 01.
Article em En | MEDLINE | ID: mdl-36436516
Assuntos
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias Gástricas / Neoplasias da Mama / Carcinoma Lobular Tipo de estudo: Etiology_studies / Guideline / Prognostic_studies / Risk_factors_studies Limite: Female / Humans Idioma: En Revista: Lancet Oncol Ano de publicação: 2023 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias Gástricas / Neoplasias da Mama / Carcinoma Lobular Tipo de estudo: Etiology_studies / Guideline / Prognostic_studies / Risk_factors_studies Limite: Female / Humans Idioma: En Revista: Lancet Oncol Ano de publicação: 2023 Tipo de documento: Article